bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 1 from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
Authors: Becht Etienne , de Reyniès Aurélien , Giraldo Nicolas A. , Pilati Camilla , Buttard Bénédicte , Lacroix Laetitia , Selves Janick , Sautès-Fridman Catherine , Laurent-Puig Pierre , Fridman Wolf Herman
Published: April 2023

Immune, and other stromal samples analyzed
Supplementary Figures from Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models with a Distinct Mechanism of Action
Authors: Yu Ziyang , He Suqin , Wang Dannie , Patel Hitisha K. , Miller Chris P. , Brown Jeffrey L. , Hattersley Gary , Saeh Jamal C.
Published: April 2023

Supplementary Figure S2. PC3-AR prostate cancer cells were transfected with ARE-luc and Renilla luciferase constructs in medium containing 5% CSS. Twenty-four hours after the transfection, cells were treated with RAD140 or DHT at the indicated final concentrations
Table S3 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients
Authors: Sun Jie , Meng Hua , Yao Lu , Lv Meng , Bai Jian , Zhang Jianguang , Wang Lientu , Ouyang Tao , Li Jinfeng , Wang Tianfeng , Fan Zhaoqing , Fan Tie , Lin Benyao , Xie Yuntao
Published: April 2023

pathogenic mutations
Figure S4 from Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Authors: Kapoor Shivani , Natarajan Karthika , Baldwin Patrick R. , Doshi Kshama A. , Lapidus Rena G. , Mathias Trevor J. , Scarpa Mario , Trotta Rossana , Davila Eduardo , Kraus Manfred , Huszar Dennis , Tron Adriana E. , Perrotti Danilo , Baer Maria R.
Published: April 2023

Combined AZD1208 and quizartinib treatment does not abrogate growth of KG-1a cells, expressing FLT3-WT, in a xenograft model.
Table S8 from PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Authors: Tarantelli Chiara , Gaudio Eugenio , Arribas Alberto J. , Kwee Ivo , Hillmann Petra , Rinaldi Andrea , Cascione Luciano , Spriano Filippo , Bernasconi Elena , Guidetti Francesca , Carrassa Laura , Pittau Roberta Bordone , Beaufils Florent , Ritschard Reto , Rageot Denise , Sele Alexander , Dossena Barbara , Rossi Francesca Maria , Zucchetto Antonella , Taborelli Monica , Gattei Valter , Rossi Davide , Stathis Anastasios , Stussi Georg , Broggini Massimo , Wymann Matthias P. , Wicki Andreas , Zucca Emanuele , Cmiljanovic Vladimir , Fabbro Doriano , Bertoni Francesco
Published: April 2023

Gene expression changes in DLBCL cell lines after exposure to PQR309.
Figure S3 from Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Authors: Kapoor Shivani , Natarajan Karthika , Baldwin Patrick R. , Doshi Kshama A. , Lapidus Rena G. , Mathias Trevor J. , Scarpa Mario , Trotta Rossana , Davila Eduardo , Kraus Manfred , Huszar Dennis , Tron Adriana E. , Perrotti Danilo , Baer Maria R.
Published: April 2023

Pim kinase and FLT3 inhibition does not enhance induction of apoptosis of cells with FLT3-WT.
Table S7 from PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Authors: Tarantelli Chiara , Gaudio Eugenio , Arribas Alberto J. , Kwee Ivo , Hillmann Petra , Rinaldi Andrea , Cascione Luciano , Spriano Filippo , Bernasconi Elena , Guidetti Francesca , Carrassa Laura , Pittau Roberta Bordone , Beaufils Florent , Ritschard Reto , Rageot Denise , Sele Alexander , Dossena Barbara , Rossi Francesca Maria , Zucchetto Antonella , Taborelli Monica , Gattei Valter , Rossi Davide , Stathis Anastasios , Stussi Georg , Broggini Massimo , Wymann Matthias P. , Wicki Andreas , Zucca Emanuele , Cmiljanovic Vladimir , Fabbro Doriano , Bertoni Francesco
Published: April 2023

Phosphopeptide changes induced by PQR309 in B cell lymphoma cell lines revealed using mass spectrometry analysis.
Table S4 from PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Authors: Tarantelli Chiara , Gaudio Eugenio , Arribas Alberto J. , Kwee Ivo , Hillmann Petra , Rinaldi Andrea , Cascione Luciano , Spriano Filippo , Bernasconi Elena , Guidetti Francesca , Carrassa Laura , Pittau Roberta Bordone , Beaufils Florent , Ritschard Reto , Rageot Denise , Sele Alexander , Dossena Barbara , Rossi Francesca Maria , Zucchetto Antonella , Taborelli Monica , Gattei Valter , Rossi Davide , Stathis Anastasios , Stussi Georg , Broggini Massimo , Wymann Matthias P. , Wicki Andreas , Zucca Emanuele , Cmiljanovic Vladimir , Fabbro Doriano , Bertoni Francesco
Published: April 2023

Baseline gene expression analysis of B cell lymphoma cell lines sensitive to PQR309 and idelalisib (dual sensitive) or to PQR309 only (discordant).
Supplementary Figure and Tables from Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer
Authors: Fan Yun , Zhu Xuehua , Xu Yan , Lu Xuesong , Xu Yanjun , Wang Mengzhao , Xu Haiyan , Ding Jingyan , Ye Xin , Fang Luo , Huang Zhiyu , Gong Lei , Lu Hongyang , Mao Weimin , Hu Min
Published: April 2023

Supple Fig 1, Supple Table 1-8, and Supple Ref. Supplementary Figure S1. 2100 Bioanalyzer spectra of total DNA extracted from CSF samples. Supplementary Table S1. Sample collection information. Supplementary Table S2. Genes/regions included in the LungPlasma panel. Supplementary Table S3. Genes included in the customized SeqCap EZ Choice Library. Supplementary Table S4. List of hotspot mutations and structural rearrangements. Supplementary Table S5. Co-existence of EGFR and PIK3CA mutations as reported in NSCLC patient datasets Supplementary Table S6. Occurrence of somatic protein-changing variants in primary tumor and CSF. Supplementary Table S7. Genes and biological pathways with recurrent somatic protein-changing variants in primary tumor or CSF. Supplementary Table S8. Comparison of EGFR mutation type(s) in CSF cfDNA and pellet DNA as detected by droplet digital PCR (ddPCR).
Supplementary Figures from Optoacoustic Detection of Early Therapy-Induced Tumor Cell Death Using a Targeted Imaging Agent
Authors: Xie Bangwen , Tomaszewski Michal R. , Neves André A. , Ros Susana , Hu De-En , McGuire Sarah , Mullins Stefanie R. , Tice David , Sainson Richard C.A. , Bohndiek Sarah E. , Wilkinson Robert W. , Brindle Kevin M.
Published: April 2023

Supplementary figures 1 - 4. Caption for video file.
Supplementary Figure 2B from The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Authors: Bozovic-Spasojevic Ivana , Zardavas Dimitrios , Brohée Sylvain , Ameye Lieveke , Fumagalli Debora , Ades Felipe , de Azambuja Evandro , Bareche Yacine , Piccart Martine , Paesmans Marianne , Sotiriou Christos
Published: April 2023

Correlation of clinical variables and AR expression in different BC subtypes: A-in Luminal A; B-in Luminal B; C-in HER2 enriched; D-in Basal like.
Supplementary Table S2 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Authors: Chatterjee Jayanta , Dai Wei , Aziz Nor Haslinda Abd , Teo Pei Yun , Wahba John , Phelps David L. , Maine Christian J. , Whilding Lynsey M. , Dina Roberto , Trevisan Giorgia , Flower Kirsty J. , George Andrew J.T. , Ghaem-Maghami Sadaf
Published: April 2023

Table showing multivariable adjusted Cox proportional-hazards models for all variables. All characteristics tested using Cox proportional hazards models in both progression free survival and overall survival analyses to determine any confounding factors
Supplementary Figure S6 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Authors: Chatterjee Jayanta , Dai Wei , Aziz Nor Haslinda Abd , Teo Pei Yun , Wahba John , Phelps David L. , Maine Christian J. , Whilding Lynsey M. , Dina Roberto , Trevisan Giorgia , Flower Kirsty J. , George Andrew J.T. , Ghaem-Maghami Sadaf
Published: April 2023

Receiver operating characteristic curves comparing individual markers and combined markers against CA-125. A: Sensitivity and specificity of discriminating EOCs from benign tumours when using PD-L1+ monocytes (AUC 0.93), PD-L1+CD14+ monocytes and PD-L1+ monocytes with PD-1+ lymphocytes combined (AUC 0.92) compared to CA-125. B: Sensitivity and specificity of discriminating HGS from benign tumours when using PD-L1+ monocytes (AUC 0.98), PD-L1+CD14+ monocytes and PD-L1+ monocytes with PD-1+ lymphocytes combined (AUC 0.97) compared to CA-125.
Supplementary Table S1: Exposures to avoid prior to metanephrine testing from Von Hippel–Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood
Authors: Rednam Surya P. , Erez Ayelet , Druker Harriet , Janeway Katherine A. , Kamihara Junne , Kohlmann Wendy K. , Nathanson Katherine L. , States Lisa J. , Tomlinson Gail E. , Villani Anita , Voss Stephan D. , Schiffman Joshua D. , Wasserman Jonathan D.
Published: April 2023

Exposures to avoid prior to metanephrine testing
Supplementary Table S1 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
Authors: Guedes Liana B. , Almutairi Fawaz , Haffner Michael C. , Rajoria Gaurav , Liu Zach , Klimek Szczepan , Zoino Roberto , Yousefi Kasra , Sharma Rajni , De Marzo Angelo M. , Netto George J. , Isaacs William B. , Ross Ashley E. , Schaeffer Edward M. , Lotan Tamara L.
Published: April 2023

Tissue cohorts included in the study
Supp Fig S3 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
Authors: Guedes Liana B. , Almutairi Fawaz , Haffner Michael C. , Rajoria Gaurav , Liu Zach , Klimek Szczepan , Zoino Roberto , Yousefi Kasra , Sharma Rajni , De Marzo Angelo M. , Netto George J. , Isaacs William B. , Ross Ashley E. , Schaeffer Edward M. , Lotan Tamara L.
Published: April 2023

Location of the mutations/deletions in TP53 gene detected by sequencing stratified p53 immunostaining result. (A) Location of the TP53 missense mutations that were detected by p53 immunostaining, showing a higher occurrence at hotspots in the DNA binding domain. (B) Location of the missense mutations, frameshifts, nonsense and splice site variants that were not detected by p53 IHC.
Supplementary Data from Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer
Authors: Brägelmann Johannes , Klümper Niklas , Offermann Anne , von Mässenhausen Anne , Böhm Diana , Deng Mario , Queisser Angela , Sanders Christine , Syring Isabella , Merseburger Axel S. , Vogel Wenzel , Sievers Elisabeth , Vlasic Ignacija , Carlsson Jessica , Andrén Ove , Brossart Peter , Duensing Stefan , Svensson Maria A. , Adler David , Kirfel Jutta , Perner Sven
Published: April 2023

Supplementary Data from Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer
Table S3 from 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
Authors: Quintela-Fandino Miguel , Lluch Ana , Manso Luis , Calvo Isabel , Cortes Javier , García-Saenz José Angel , Gil-Gil Miguel , Martinez-Jánez Noelia , Gonzalez-Martin Antonio , Adrover Encarna , de Andres Raquel , Viñas Gemma , Llombart-Cussac Antonio , Alba Emilio , Guerra Juan , Bermejo Begoña , Zamora Esther , Moreno-Anton Fernando , Pernas Simon Sonia , Carrato Alfredo , Lopez-Alonso Antonio , Escudero María José , Campo Ruth , Carrasco Eva , Palacios José , Mulero Francisca , Colomer Ramon
Published: April 2023

Hypoxic volumes
Supplemental Table 2 from Identification of Keratin 19–Positive Cancer Stem Cells Associating Human Hepatocellular Carcinoma Using 18F-Fluorodeoxyglucose Positron Emission Tomography
Authors: Kawai Takayuki , Yasuchika Kentaro , Seo Satoru , Higashi Tatsuya , Ishii Takamichi , Miyauchi Yuya , Kojima Hidenobu , Yamaoka Ryoya , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Nakamoto Yuji , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Primer sequences for RT-PCR and qRT-PCR.
Supplementary figure legends from 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
Authors: Quintela-Fandino Miguel , Lluch Ana , Manso Luis , Calvo Isabel , Cortes Javier , García-Saenz José Angel , Gil-Gil Miguel , Martinez-Jánez Noelia , Gonzalez-Martin Antonio , Adrover Encarna , de Andres Raquel , Viñas Gemma , Llombart-Cussac Antonio , Alba Emilio , Guerra Juan , Bermejo Begoña , Zamora Esther , Moreno-Anton Fernando , Pernas Simon Sonia , Carrato Alfredo , Lopez-Alonso Antonio , Escudero María José , Campo Ruth , Carrasco Eva , Palacios José , Mulero Francisca , Colomer Ramon
Published: April 2023

Figure S1 legend
Supplemental Figure Legends from Identification of Keratin 19–Positive Cancer Stem Cells Associating Human Hepatocellular Carcinoma Using 18F-Fluorodeoxyglucose Positron Emission Tomography
Authors: Kawai Takayuki , Yasuchika Kentaro , Seo Satoru , Higashi Tatsuya , Ishii Takamichi , Miyauchi Yuya , Kojima Hidenobu , Yamaoka Ryoya , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Nakamoto Yuji , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Legends for supplemental Figure 1-3.
Supplementary Table S3 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Authors: Wheeler Heather E. , Gamazon Eric R. , Frisina Robert D. , Perez-Cervantes Carlos , El Charif Omar , Mapes Brandon , Fossa Sophie D. , Feldman Darren R. , Hamilton Robert J. , Vaughn David J. , Beard Clair J. , Fung Chunkit , Kollmannsberger Christian , Kim Jeri , Mushiroda Taisei , Kubo Michiaki , Ardeshir-Rouhani-Fard Shirin , Einhorn Lawrence H. , Cox Nancy J. , Dolan M. Eileen , Travis Lois B.
Published: April 2023

Top SNPs (P < 1 x 10-5) in the meta-analysis of The Platinum Study and St. Jude cohorts.
Supplemental Figure 1 from Identification of Keratin 19–Positive Cancer Stem Cells Associating Human Hepatocellular Carcinoma Using 18F-Fluorodeoxyglucose Positron Emission Tomography
Authors: Kawai Takayuki , Yasuchika Kentaro , Seo Satoru , Higashi Tatsuya , Ishii Takamichi , Miyauchi Yuya , Kojima Hidenobu , Yamaoka Ryoya , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Nakamoto Yuji , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Flow of the patients through the study.
Supplementary Figure S4 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Authors: Wheeler Heather E. , Gamazon Eric R. , Frisina Robert D. , Perez-Cervantes Carlos , El Charif Omar , Mapes Brandon , Fossa Sophie D. , Feldman Darren R. , Hamilton Robert J. , Vaughn David J. , Beard Clair J. , Fung Chunkit , Kollmannsberger Christian , Kim Jeri , Mushiroda Taisei , Kubo Michiaki , Ardeshir-Rouhani-Fard Shirin , Einhorn Lawrence H. , Cox Nancy J. , Dolan M. Eileen , Travis Lois B.
Published: April 2023

Top GWAS SNP rs62283056 is a cis-acting eQTL for WFS1 in several tissues.
Supplementary Figure and Tables from BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer
Authors: Summers Matthew G. , Smith Christopher G. , Maughan Timothy S. , Kaplan Richard , Escott-Price Valentina , Cheadle Jeremy P.
Published: April 2023

Figure - Correlation plot showing inter- and intra-genic relationships between somatic KRAS, BRAF and NRAS mutations and MSI status in aCRC. Tables - Heterogeneity Tests comparing OS to diagnosis to death (Table S1) and the effect of cetuximab on OS (Table S2).
Supplementary Figure S3 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Authors: Wheeler Heather E. , Gamazon Eric R. , Frisina Robert D. , Perez-Cervantes Carlos , El Charif Omar , Mapes Brandon , Fossa Sophie D. , Feldman Darren R. , Hamilton Robert J. , Vaughn David J. , Beard Clair J. , Fung Chunkit , Kollmannsberger Christian , Kim Jeri , Mushiroda Taisei , Kubo Michiaki , Ardeshir-Rouhani-Fard Shirin , Einhorn Lawrence H. , Cox Nancy J. , Dolan M. Eileen , Travis Lois B.
Published: April 2023

Robustness of the enrichment of top GWAS SNPs in Mendelian deafness genes.
Supplementary Table 3 from Landscape of Genomic Alterations in Pituitary Adenomas
Authors: Bi Wenya Linda , Horowitz Peleg , Greenwald Noah F. , Abedalthagafi Malak , Agarwalla Pankaj K. , Gibson Wiliam J. , Mei Yu , Schumacher Steven E. , Ben-David Uri , Chevalier Aaron , Carter Scott , Tiao Grace , Brastianos Priscilla K. , Ligon Azra H. , Ducar Matthew , MacConaill Laura , Laws Edward R. , Santagata Sandro , Beroukhim Rameen , Dunn Ian F.
Published: April 2023

Comparison of gene expression levels
Supplementary Table 6 and Table 7 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer
Authors: Xu Jian-Ming , Wang Yan , Wang You-Liang , Liu Tao , Ni Ming , Li Man-Sheng , Lin Li , Ge Fei-Jiao , Gong Chun , Gu Jun-Yan , Jia Ru , Wang He-Fei , Chen Yu-Ling , Liu Rong-Rui , Zhao Chuan-Hua , Tan Zhao-Li , Jin Yang , Zhu Yun-Ping , Ogino Shuji , Qian Zhi-Rong
Published: April 2023

Comparison of RAS or PIK3CA mutations between left- and right- colon in tumor tissue and ctDNA
Supplementary Table 2 from Landscape of Genomic Alterations in Pituitary Adenomas
Authors: Bi Wenya Linda , Horowitz Peleg , Greenwald Noah F. , Abedalthagafi Malak , Agarwalla Pankaj K. , Gibson Wiliam J. , Mei Yu , Schumacher Steven E. , Ben-David Uri , Chevalier Aaron , Carter Scott , Tiao Grace , Brastianos Priscilla K. , Ligon Azra H. , Ducar Matthew , MacConaill Laura , Laws Edward R. , Santagata Sandro , Beroukhim Rameen , Dunn Ian F.
Published: April 2023

Characteristics of 87 pituitary adenomas from validation cohort
Supplementary Figure S1 from Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy
Authors: Mancarella Caterina , Pasello Michela , Ventura Selena , Grilli Andrea , Calzolari Linda , Toracchio Lisa , Lollini Pier-Luigi , Donati Davide Maria , Picci Piero , Ferrari Stefano , Scotlandi Katia
Published: April 2023

Scatter plot analysis of IGF2BP1, IGF2BP2, IGF2BP3 and ABCF1 in ES clinical samples
Supplemental Table S1: Terminology definitions as used by the Precision Oncology Decision Support (PODS) team at MD Anderson Cancer Center from Precision Oncology Decision Support: Current Approaches and Strategies for the Future
Authors: Kurnit Katherine C. , Dumbrava Ecaterina E. Ileana , Litzenburger Beate , Khotskaya Yekaterina B. , Johnson Amber M. , Yap Timothy A. , Rodon Jordi , Zeng Jia , Shufean Md Abu , Bailey Ann M. , Sánchez Nora S. , Holla Vijaykumar , Mendelsohn John , Shaw Kenna Mills , Bernstam Elmer V. , Mills Gordon B. , Meric-Bernstam Funda
Published: April 2023

Terminology definitions as used by the Precision Oncology Decision Support (PODS) team at MD Anderson Cancer Center
Supplemental Table 4 from The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes
Authors: Salomon Matthew P. , Wang Xiaowen , Marzese Diego M. , Hsu Sandy C. , Nelson Nellie , Zhang Xin , Matsuba Chikako , Takasumi Yuki , Ballesteros-Merino Carmen , Fox Bernard A. , Barkhoudarian Garni , Kelly Daniel F. , Hoon Dave S.B.
Published: April 2023

ACTH-secreting PAs starburst plot gene details. The top 50 most significantly differentially expressed genes contained within Figure 5 for ACTH-secreting PAs as compared to endocrine-inactive PAs. The table has five columns; 1) gene symbol, 2) Entrez ID number, 3) the log fold change value from the RNA-seq differential expression analysis comparing ACTH-secreting PAs to endocrine-inactive PAs, 4) the change in methylation beta values between ACTH-secreting PAs and endocrine-inactive PAs, and 5) the genomic feature for the methylation data.
Supplementary Fig Legends from Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib
Authors: Liu Shengwu , Li Shuai , Hai Josephine , Wang Xiaoen , Chen Ting , Quinn Max M. , Gao Peng , Zhang Yanxi , Ji Hongbin , Cross Darren A.E. , Wong Kwok-Kin
Published: April 2023

Figure legends for supplementary Figure S1-S3
Figure S6 from Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies
Authors: Cooney Jeffrey D. , Lin An-Ping , Jiang Daifeng , Wang Long , Suhasini Avvaru N. , Myers Jamie , Qiu ZhiJun , Wölfler Albert , Sill Heinz , Aguiar Ricardo C.T.
Published: April 2023

Cell viability CLL
Figure S5 from Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer
Authors: Post Annemarie E.M. , Smid Marcel , Nagelkerke Anika , Martens John W.M. , Bussink Johan , Sweep Fred C.G.J. , Span Paul N.
Published: April 2023

Protein expression of ISGs in human breast tumors
Figure S4 from Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer
Authors: Post Annemarie E.M. , Smid Marcel , Nagelkerke Anika , Martens John W.M. , Bussink Johan , Sweep Fred C.G.J. , Span Paul N.
Published: April 2023

Correlation of ISG expression levels to outcome in patients with advanced breast cancer
Supplementary Figures and Tables from Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma
Authors: Nakashima Hiroshi , Nguyen Tran , Kasai Kazue , Passaro Carmela , Ito Hirotaka , Goins William F. , Shaikh Imran , Erdelyi Ronald , Nishihara Reiko , Nakano Ichiro , Reardon David A. , Anderson Ana C. , Kuchroo Vijay , Chiocca E. Antonio
Published: April 2023

Supplementary Table 1. Dose-response effects of human glioblastoma cells after treatment with NG34 or rQNestin34.5. Supplementary Figure S1. A, The dose-response curves represent cell viability assay for human astrocytes. Intracellular ATP was measured as an index of cell viability, five days after infection of human astrocyte cells with NG34 or rQNestin34.5. Data were normalized to maximum and minimum values before plotting the averaged values of six replicates with S.D. error bars and non-linear dose-response curves. Ranges of 50% effective doses (ED50) at 95% confidence intervals are 0.00094-0.0034 pfu (NG34) and 0.0011-0.0024 puf (rQNestin34.5), and values of R2 are 0.9423 (NG34) and 0.9748 (rQNestin34.5), respectively. B, viral replication in normal tissues was measured by titrating viral yields collected from cultured human astrocytes after HSV1 F strain (wild-type), rHSVQ, NG34 or rQNestin34.5 at 0.1 of their MOIs. Error bars represent S.D (n = 4). Supplementary Figure S2. The dose-response curves represent are obtained from the cell viability assay used in Table. 1. Supplementary Figure S3. NG34-gCRliFluc and rHSVQ-gCRliFluc oHSV were generated as described in the Materials and Methods section . Supplementary Figure S4. Bioluminescent imaging of xenografted human glioma indicates tumor regression upon oHSV treatment. Supplementary Figure S5. Reproducibility of therapeutic efficacy of NG34 in different models in vivo. Supplementary Figure S6. Gene expression of cytokines in mouse brains with NG34 inoculation. Supplementary Figure S7. Immunohistochemistry of the brains of athymic mice after the HSV-1 inoculation.
Supplemental Figures from UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models
Authors: DeRyckere Deborah , Lee-Sherick Alisa B. , Huey Madeline G. , Hill Amanda A. , Tyner Jeffrey W. , Jacobsen Kristen M. , Page Lauren S. , Kirkpatrick Gregory G. , Eryildiz Fatma , Montgomery Stephanie A. , Zhang Weihe , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Graham Douglas K.
Published: April 2023

Supplemental Figure 1: UNC2025 induces apoptosis, alters cell cycle progression, and inhibits expansion of leukemia cell lines in culture. Supplemental Figure 2: UNC2025 inhibits cells growth in AML patient samples. Supplemental Figure 3: UNC2025 inhibits MERTK phosphorylation in bone marrow leukemia cells in an orthotopic murine B-ALL xenograft model. Supplemental Figure 4: Treatment with UNC2025 alters bone marrow progenitor populations. Supplemental Figure 5: Treatment with UNC2025 alters bone marrow progenitor populations but has minimal effect on blood electrolytes, liver enzymes, and retinal pathology.
Supp Fig S1-S5 and Supp Tables S1-S2 from CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma through the Upregulation of Slug
Authors: Chung Man Ki , Jung Young Ho , Lee Joon Kyoo , Cho Soo Youn , Murillo-Sauca Oihana , Uppaluri Ravindra , Shin June Ho , Sunwoo John B.
Published: April 2023

Supplementary Figure S1. Comparisons of mRNA expressions of EMTrelated genes (Vimentin, CDH1, CDH2, Twist1, TGFÃŸ1) between MOC2 vs MOC2-CD271 cells, and between HSC3 vs HSC3-CD271 cells by qRT-PCR; Supplementary Figure S2. Comparisons of mRNA expression of ligands (NGF, BDNF, NT-4) for the CD271 receptor between CD45+ cells, stromal cells and tumors by qRTPCR; Supplementary Figure S3. Representative photomicrographs of morphologic changes of murine or human cancer cells (MOC2-CD271, HSC3-CD271, respectively) in response to rhNGF-Î² treatment for 48 hrs; Supplementary Figure S4. CD271 activation induces Snai2 expression through the ERK1/2 pathway; Supplementary figure S5. Quantification methods for CD271 expression in primary oral tumor by immunohistochemistry using Photoshop and Image J; Supplementary Table 1. Profiles of patients with oral squamous cell carcinoma analyzed by immunohistochemistry CD271 expression; Supplemental Table 2. Cox proportional hazard model to identify predictors of disease-free survival in pN+ patients.
Supplemental Methods from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
Authors: Lang Jessica D. , Hendricks William P.D. , Orlando Krystal A. , Yin Hongwei , Kiefer Jeffrey , Ramos Pilar , Sharma Ritin , Pirrotte Patrick , Raupach Elizabeth A. , Sereduk Chris , Tang Nanyun , Liang Winnie S. , Washington Megan , Facista Salvatore J. , Zismann Victoria L. , Cousins Emily M. , Major Michael B. , Wang Yemin , Karnezis Anthony N. , Sekulic Aleksandar , Hass Ralf , Vanderhyden Barbara C. , Nair Praveen , Weissman Bernard E. , Huntsman David G. , Trent Jeffrey M.
Published: April 2023

Supplemental Materials and Methods
Supplementary Table 3 and Analysis Scripts from Discovery and Validation of Circulating Biomarkers of Colorectal Adenoma by High-Depth Small RNA Sequencing
Authors: Roberts Brian S. , Hardigan Andrew A. , Moore Dianna E. , Ramaker Ryne C. , Jones Angela L. , Fitz-Gerald Meredith B. , Cooper Gregory M. , Wilcox C. Mel , Kimberly Robert P. , Myers Richard M.
Published: April 2023

A large Excel sheet of data and the complete set of scripts used to analyze the data.
Table S1 from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer
Authors: Hamilton Erika P. , Patel Manish R. , Armstrong Anne C. , Baird Richard D. , Jhaveri Komal , Hoch Matthias , Klinowska Teresa , Lindemann Justin P.O. , Morgan Shethah R. , Schiavon Gaia , Weir Hazel M. , Im Seock-Ah
Published: April 2023

PK parameters for M3 following a single dose (Day 1) and multiple doses (Day 15)
Figure S2A and S2B: Geometric mean plasma concentration-time profiles of AZD9496 metabolites M3 (A and B) and M5 (C and D) following a single dose and multiple doses of AZD9496 (n = 3-5 subjects) from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer
Authors: Hamilton Erika P. , Patel Manish R. , Armstrong Anne C. , Baird Richard D. , Jhaveri Komal , Hoch Matthias , Klinowska Teresa , Lindemann Justin P.O. , Morgan Shethah R. , Schiavon Gaia , Weir Hazel M. , Im Seock-Ah
Published: April 2023

GAZD9496 metabolite, M3 (Panel A) and M5 (Panel C), geometric mean plasma concentration following a single dose of AZD9496 on Day 1 (semi-log scale). AZD9496 metabolite, M3 (Panel B) and M5 (Panel D), geometric mean plasma concentration following multiple doses of AZD9496 on Day 15 (semi-log scale). On Day 15 at all doses except 20 mg, the 24 h time point is the 12 h trough concentration following the evening dose of AZD9496 and therefore not shown. aPooled data from dose escalation and expansion groups. BID=twice daily; QD=once daily; EXP=expansion cohort.
Supplementary data from Development and Preclinical Validation of a Cysteine Knottin Peptide Targeting Integrin αvβ6 for Near-infrared Fluorescent-guided Surgery in Pancreatic Cancer
Authors: Tummers Willemieke S. , Kimura Richard H. , Abou-Elkacem Lotfi , Beinat C. , Vahrmeijer Alexander L. , Swijnenburg Rutger-Jan , Willmann Juergen K. , Gambhir Sanjiv S.
Published: April 2023

Figure S1 shows mass spectometry results of the targeting agent (A), and control peptide (B). It also shows photostability of agent. Figure S2 shows characterisation of the different cell lines used. Figure S3 shows the difference in fluorescence between PDAC and peritumoral inflammation Figure S4 shows results of the preliminary toxicity study in mice
Supplementary Table 4 from A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers
Authors: Banerji Udai , Dean Emma J. , Pérez-Fidalgo J. Alejandro , Batist Gerald , Bedard Philippe L. , You Benoit , Westin Shannon N. , Kabos Peter , Garrett Michelle D. , Tall Mathew , Ambrose Helen , Barrett J. Carl , Carr T. Hedley , Cheung S.Y. Amy , Corcoran Claire , Cullberg Marie , Davies Barry R. , de Bruin Elza C. , Elvin Paul , Foxley Andrew , Lawrence Peter , Lindemann Justin P.O. , Maudsley Rhiannon , Pass Martin , Rowlands Vicky , Rugman Paul , Schiavon Gaia , Yates James , Schellens Jan H.M.
Published: April 2023

Supplementary Table 4. Tables with results of molecular analyses of Part C patients (PIK3CA and ESR1 mutation status in tissue and ctDNA, PTEN status in archival tissue)
Supplemental Figure 1 from TFAP2E Methylation and Expression Status Does Not Predict Response to 5-FU-based Chemotherapy in Colorectal Cancer
Authors: Murcia Oscar , Jover Rodrigo , Egoavil Cecilia , Perez-Carbonell Lucia , Juárez Miriam , Hernández-Illán Eva , Rojas Estefania , Alenda Cristina , Balaguer Francesc , Andreu Montserrat , Llor Xavier , Castells Antoni , Boland C. Richard , Goel Ajay
Published: April 2023

Supplementary Figure 1. Schematic representation of TFAP2E gene. The gene encoding transcription factor AP-2 epsilon (TFAP2E) is located on chromosome 1p34. In the schematic overview, exons are represented by blue boxes and introns with blue lines. The TFAP2E gene has two cytosine-phosphate-guanine (CpG) islands underscoring the potential of gene expression by means of CpG hypermethylation (green boxes). We used two quantitative methods, QMSP and pyrosequencing, covering both CpG islands in order to correlate methylation levels at these two locations.
Supp Figure 4 from TFAP2E Methylation and Expression Status Does Not Predict Response to 5-FU-based Chemotherapy in Colorectal Cancer
Authors: Murcia Oscar , Jover Rodrigo , Egoavil Cecilia , Perez-Carbonell Lucia , Juárez Miriam , Hernández-Illán Eva , Rojas Estefania , Alenda Cristina , Balaguer Francesc , Andreu Montserrat , Llor Xavier , Castells Antoni , Boland C. Richard , Goel Ajay
Published: April 2023

Supplementary Figure 4. Epicolon I. Overall Survival Stage IV Patients: TFAP2E IHC Expression. Disease Free Survival Stage II and III Patients: TFAP2E IHC Expression. (A) Overall survival of patients with stage IV disease, according to TFAP2E expression status comparing staining scores 0 & 1 (Low expression) vs staining scores 2 & 3 (High expression;). (B) Overall survival of patients that received or did not receive (C) 5-FU based chemotherapy according to TFAP2E expression status. (D) Disease Free Survival (DFS) of patients with stage II and III CRC, according to TFAP2E expression status comparing staining scores 0 & 1 (Low expression) vs staining scores 2 & 3 (High expression) (E) DFS of stages II+III CRC patients that received or did not receive (F)) adjuvant chemotherapy according to TFAP2E expression status.
Figure S6 from Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1
Authors: Shah Deep , Wyatt Debra , Baker Andrew T. , Simms Patricia , Peiffer Daniel S. , Fernandez Michelle , Rakha Emad , Green Andrew , Filipovic Alexandra , Miele Lucio , Osipo Clodia
Published: April 2023

Lapatinib-induced Jagged1 high expressing cells have higher Aldefluor activity.
Figure S2 from Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1
Authors: Shah Deep , Wyatt Debra , Baker Andrew T. , Simms Patricia , Peiffer Daniel S. , Fernandez Michelle , Rakha Emad , Green Andrew , Filipovic Alexandra , Miele Lucio , Osipo Clodia
Published: April 2023

Authentication of Jagged1 antibody for flow cytometry.
SuppData from Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
Authors: Savona Michael R. , Pollyea Daniel A. , Stock Wendy , Oehler Vivian G. , Schroeder Mark A. , Lancet Jeffrey , McCloskey James , Kantarjian Hagop M. , Ma Weidong Wendy , Shaik M. Naveed , Laird A. Douglas , Zeremski Mirjana , O'Connell Ashleigh , Chan Geoffrey , Cortes Jorge E.
Published: April 2023

Additional Methods: MTD determination; Biomarker analyzed Supplementary Table S1. Patient disposition by treatment group Supplementary Table S2. Treatment-related AEs reported in >10% of patients in arm A Supplementary Table S3. Treatment-related AEs reported in in {greater than or equal to}2 patients in arm B Supplementary Table S4. Treatment-related AEs reported in >20% of patients in arm C Supplementary Table S5 Median treatment duration and dose reductions/delays by treatment group Supplementary Table S6. Treatment discontinuations by treatment group Supplementary Table S7. Glasdegib pharmacokinetic parameters at the RP2D Supplementary Table S8. Best overall response in patients with AML by treatment arm Supplementary Table S9. Selected baseline characteristics including gene mutations and response to treatment Supplementary Figure S1. Potential associations of MMP-3 and SDF-1 with response in patients administered glasdegib plus cytarabine/daunorubicin
Supplemental Figures from t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells
Authors: Lenz Gal , Hamilton Angelica , Geng Shuhui , Hong Teresa , Kalkum Markus , Momand Jamil , Kane Susan E. , Huss Janice M.
Published: April 2023

Figure S1. Protein levels of PPP1R1B and IGF-1R. Figure S2. Comparison of respiration rates in SK-BR-3 parental and derived cell lines. Figure S3. siRNA knockdown of IGF-1R and IR. Figure S4. The effect of recombinant t-Darpp on oxygen consumption rate (OCR) of SK-BR-3 cells. Figure S5. Western analysis of IGF-1R and Akt phosphorylation in L6 myotubes by treatment with recombinant t-Darpp. Figure S6. Relative endogenous receptor levels in SK-BR-3 and derived cell lines.
Table S4 from Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling
Authors: Ye Mingxiang , Zhang Yong , Gao Hongjun , Xu Yan , Jing Pengyu , Wu Jianxiong , Zhang Xinxin , Xiong Jie , Dong Chenfang , Yao Libo , Zhang Jian
Published: April 2023

Antibody sources for Western blot, IP, immunofluorescence and IHC.
Table S3 from Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
Authors: Villarroel-Espindola Franz , Yu Xiaoqing , Datar Ila , Mani Nikita , Sanmamed Miguel , Velcheti Vamsidhar , Syrigos Konstantinos , Toki Maria , Zhao Hongyu , Chen Lieping , Herbst Roy S. , Schalper Kurt A.
Published: April 2023

Description of cohort #3
Table S2 from Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling
Authors: Ye Mingxiang , Zhang Yong , Gao Hongjun , Xu Yan , Jing Pengyu , Wu Jianxiong , Zhang Xinxin , Xiong Jie , Dong Chenfang , Yao Libo , Zhang Jian
Published: April 2023

PCR primer sequence for mutagenesis (5'â†'3').
Supplementary Figures S1-S6 from Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling
Authors: Ye Mingxiang , Zhang Yong , Gao Hongjun , Xu Yan , Jing Pengyu , Wu Jianxiong , Zhang Xinxin , Xiong Jie , Dong Chenfang , Yao Libo , Zhang Jian
Published: April 2023

Supplementary Figures S1-S6 suggest that AhR signaling activation leads to EGFR TKIs resistance, in which AhR protein recruits Src to Jak2 to restore PI3K/Akt and MEK/Erk signaling.
Supplementary figure legends from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
Authors: Luk Iris Sze Ue , Shrestha Raunak , Xue Hui , Wang Yuwei , Zhang Fang , Lin Dong , Haegert Anne , Wu Rebecca , Dong Xin , Collins Colin C. , Zoubeidi Amina , Gleave Martin E. , Gout Peter W. , Wang Yuzhuo
Published: April 2023

Supplementary figure legends
Supplementary figure S6 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
Authors: Luk Iris Sze Ue , Shrestha Raunak , Xue Hui , Wang Yuwei , Zhang Fang , Lin Dong , Haegert Anne , Wu Rebecca , Dong Xin , Collins Colin C. , Zoubeidi Amina , Gleave Martin E. , Gout Peter W. , Wang Yuzhuo
Published: April 2023

Hoechst 33258 staining of LTL-313BR tumours in Scrb or ASO-6w2 treated mice. White arrows indicate nuclei of mouse fibroblasts
Supplementary Table S2 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
Authors: Luk Iris Sze Ue , Shrestha Raunak , Xue Hui , Wang Yuwei , Zhang Fang , Lin Dong , Haegert Anne , Wu Rebecca , Dong Xin , Collins Colin C. , Zoubeidi Amina , Gleave Martin E. , Gout Peter W. , Wang Yuzhuo
Published: April 2023

Gene expression changes in GPCR signalling genesets associated with ASO-6w2 treatment of LTL-313BR xenografts
Table S1 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Authors: Yonesaka Kimio , Haratani Koji , Takamura Shiki , Sakai Hitomi , Kato Ryoji , Takegawa Naoki , Takahama Takayuki , Tanaka Kaoru , Hayashi Hidetoshi , Takeda Masayuki , Kato Sigeki , Maenishi Osamu , Sakai Kazuko , Chiba Yasutaka , Okabe Takafumi , Kudo Keita , Hasegawa Yoshikazu , Kaneda Hiroyasu , Yamato Michiko , Hirotani Kenji , Miyazawa Masaaki , Nishio Kazuto , Nakagawa Kazuhiko
Published: April 2023

Characteristics of patients treated with anti-PD-1 antibody
Supplemental Table 5 from Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
Authors: Yang Zhe , Yang Nong , Ou Qiuxiang , Xiang Yi , Jiang Tao , Wu Xue , Bao Hua , Tong Xiaoling , Wang Xiaonan , Shao Yang W. , Liu Yunpeng , Wang Yan , Zhou Caicun
Published: April 2023

Supplemental Table 5
Supplemental Table 4 from Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
Authors: Yang Zhe , Yang Nong , Ou Qiuxiang , Xiang Yi , Jiang Tao , Wu Xue , Bao Hua , Tong Xiaoling , Wang Xiaonan , Shao Yang W. , Liu Yunpeng , Wang Yan , Zhou Caicun
Published: April 2023

Supplemental Table 4
Supplemental Table 3 from Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
Authors: Yang Zhe , Yang Nong , Ou Qiuxiang , Xiang Yi , Jiang Tao , Wu Xue , Bao Hua , Tong Xiaoling , Wang Xiaonan , Shao Yang W. , Liu Yunpeng , Wang Yan , Zhou Caicun
Published: April 2023

Supplemental Table 3
Sup file 3 from Lymph Node Metastases in Colon Cancer Are Polyclonal
Authors: Ulintz Peter J. , Greenson Joel K. , Wu Rong , Fearon Eric R. , Hardiman Karin M.
Published: April 2023

CNV profiles
Sup Tables from Lymph Node Metastases in Colon Cancer Are Polyclonal
Authors: Ulintz Peter J. , Greenson Joel K. , Wu Rong , Fearon Eric R. , Hardiman Karin M.
Published: April 2023

1. SNP array metrics 2. Mutation counts
Sup File 2 from Lymph Node Metastases in Colon Cancer Are Polyclonal
Authors: Ulintz Peter J. , Greenson Joel K. , Wu Rong , Fearon Eric R. , Hardiman Karin M.
Published: April 2023

Somatic Mutations
Sup Fig 1 from Lymph Node Metastases in Colon Cancer Are Polyclonal
Authors: Ulintz Peter J. , Greenson Joel K. , Wu Rong , Fearon Eric R. , Hardiman Karin M.
Published: April 2023

Analysis Workflow
Supplementary Data from Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia
Authors: Jiang Xuejie , Mak Po Yee , Mu Hong , Tao Wenjing , Mak Duncan H. , Kornblau Steven , Zhang Qi , Ruvolo Peter , Burks Jared K. , Zhang Weiguo , McQueen Teresa , Pan Rongqing , Zhou Hongsheng , Konopleva Marina , Cortes Jorge , Liu Qifa , Andreeff Michael , Carter Bing Z.
Published: April 2023

Supplementary Figures and Tables
Table S3 from Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis
Authors: Aushev Vasily N. , Lee Eunjee , Zhu Jun , Gopalakrishnan Kalpana , Li Qian , Teitelbaum Susan L. , Wetmur James , Degli Esposti Davide , Hernandez-Vargas Hector , Herceg Zdenko , Parada Humberto , Santella Regina M. , Gammon Marilie D. , Chen Jia
Published: April 2023

Table S3 (Excel file). Association of profiled genes with breast cancer mortality among participants in the LIBCSP, in different subsets or adjustments. For all analyses, age and tumor stage were included as cofactors; "ERPR_all" - included all patients; "ERPR_pos" - ER|PR+ patients; "ERPR_neg" - ER-/PR- patients; "ERPR_adj" - all patients, with ER/PR status as additional cofactor; "ROR_adj" - all patients, with ROR group as additional cofactor; "ROR_high" - patients assigned to high ROR group; "ROR_low+med" - patients assigned to low and medium ROR groups. For each analysis, columns are as follows: HR - hazard ratio; HR.CI - 95% confidence interval for HR; p - unadjusted p-value; p.BH - Benjamini-Hochberg-adjusted p-value; q - decile threshold for high/low expression level stratification; N.hi - number of patients in "high expression" group.
Figure S3 from Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis
Authors: Aushev Vasily N. , Lee Eunjee , Zhu Jun , Gopalakrishnan Kalpana , Li Qian , Teitelbaum Susan L. , Wetmur James , Degli Esposti Davide , Hernandez-Vargas Hector , Herceg Zdenko , Parada Humberto , Santella Regina M. , Gammon Marilie D. , Chen Jia
Published: April 2023

Fig. S3. Distribution of expression levels among genes and samples. Each dot represents a gene, with horizontal axis showing the percent of samples expressing this gene and vertical axis showing median log2 expression level of this gene.
Table S1 from High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma
Authors: Sandulache Vlad C. , Michikawa Chieko , Kataria Pranav , Gleber-Netto Frederico O. , Bell Diana , Trivedi Sanchit , Rao Xiayu , Wang Jing , Zhao Mei , Jasser Samar , Myers Jeffrey N. , Pickering Curtis R.
Published: April 2023

Table S1 from High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma
Supplementary Table 1 from The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma
Authors: Keane Colm , Gould Clare , Jones Kimberley , Hamm David , Talaulikar Dipti , Ellis Jonathan , Vari Frank , Birch Simone , Han Erica , Wood Peter , Le-Cao Kim-Anh , Green Michael R. , Crooks Pauline , Jain Sanjiv , Tobin Josh , Steptoe Raymond J. , Gandhi Maher K.
Published: April 2023

Individual results of TCR sequencing for all DLBCL and non-diseased nodal tissues.
Supplementary figure 1 legend from Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
Authors: Zhang Jingli , Khanna Swati , Jiang Qun , Alewine Christine , Miettinen Markku , Pastan Ira , Hassan Raffit
Published: April 2023

Semiquantitative assessment of mesothelin expression using H-score in mesothelioma patient derived xenografts. (A) NCI-Meso16: tumor with areas of strong membrane staining and intermingling of negative areas (H-score 230). (B) NCI-Meso21: tumor shows only focal membrane positivity (H-score 50). (C) NCI-Meso29: tumor shows nearly uniform strong membrane positivity (H-score 290). Original magnification 400x.
Supplementary Methods from Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study
Authors: Pietrantonio Filippo , Fucà Giovanni , Morano Federica , Gloghini Annunziata , Corso Simona , Aprile Giuseppe , Perrone Federica , De Vita Ferdinando , Tamborini Elena , Tomasello Gianluca , Gualeni Ambra Vittoria , Ongaro Elena , Busico Adele , Giommoni Elisa , Volpi Chiara Costanza , Laterza Maria Maddalena , Corallo Salvatore , Prisciandaro Michele , Antista Maria , Pellegrinelli Alessandro , Castagnoli Lorenzo , Pupa Serenella M. , Pruneri Giancarlo , de Braud Filippo , Giordano Silvia , Cremolini Chiara , Di Bartolomeo Maria
Published: April 2023

Online Methods